<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">OR</journal-id>
<journal-title-group>
<journal-title>Oncology Reports</journal-title></journal-title-group>
<issn pub-type="ppub">1021-335X</issn>
<issn pub-type="epub">1791-2431</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name></publisher></journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/or.2015.4478</article-id>
<article-id pub-id-type="publisher-id">or-35-03-1622</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject></subj-group></article-categories>
<title-group>
<article-title>Liver epithelial cells inhibit proliferation and invasiveness of hepatoma cells</article-title></title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>JENG</surname><given-names>KUO-SHYANG</given-names></name><xref rid="af1-or-35-03-1622" ref-type="aff">1</xref><xref rid="af2-or-35-03-1622" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>JENG</surname><given-names>CHI-JUEI</given-names></name><xref rid="af3-or-35-03-1622" ref-type="aff">3</xref></contrib>
<contrib contrib-type="author">
<name><surname>JENG</surname><given-names>WEN-JUEI</given-names></name><xref rid="af4-or-35-03-1622" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author">
<name><surname>SHEEN</surname><given-names>I-SHYAN</given-names></name><xref rid="af4-or-35-03-1622" ref-type="aff">4</xref></contrib>
<contrib contrib-type="author">
<name><surname>LI</surname><given-names>SHIH-YUN</given-names></name><xref rid="af2-or-35-03-1622" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>HUNG</surname><given-names>ZIH-HANG</given-names></name><xref rid="af1-or-35-03-1622" ref-type="aff">1</xref><xref rid="af2-or-35-03-1622" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>HSIAU</surname><given-names>HSIN-I</given-names></name><xref rid="af2-or-35-03-1622" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>YU</surname><given-names>MING-CHE</given-names></name><xref rid="af2-or-35-03-1622" ref-type="aff">2</xref></contrib>
<contrib contrib-type="author">
<name><surname>CHANG</surname><given-names>CHIUNG-FANG</given-names></name><xref rid="af1-or-35-03-1622" ref-type="aff">1</xref><xref rid="af2-or-35-03-1622" ref-type="aff">2</xref><xref ref-type="corresp" rid="c1-or-35-03-1622"/></contrib></contrib-group>
<aff id="af1-or-35-03-1622">
<label>1</label>Department of Surgery, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C.</aff>
<aff id="af2-or-35-03-1622">
<label>2</label>Department of Medical Research, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C.</aff>
<aff id="af3-or-35-03-1622">
<label>3</label>Department of Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan, R.O.C.</aff>
<aff id="af4-or-35-03-1622">
<label>4</label>Department of Hepato-Gastroenterology, Chang-Gung Memorial Hospital, LinKou Medical Center, Chang-Gung University, Taipei, Taiwan, R.O.C.</aff>
<author-notes>
<corresp id="c1-or-35-03-1622">Correspondence to: Dr Chiung-Fang Chang, Department of Medical Research, Far Eastern Memorial Hospital, 21 Section 2, Nanya S. Road, Banciao, New Taipei City 220, Taiwan, R.O.C., E-mail: <email>cfchang.gina@gmail.com</email></corresp></author-notes>
<pub-date pub-type="ppub">
<month>03</month>
<year>2016</year></pub-date>
<pub-date pub-type="epub">
<day>08</day>
<month>12</month>
<year>2015</year></pub-date>
<volume>35</volume>
<issue>3</issue>
<fpage>1622</fpage>
<lpage>1628</lpage>
<history>
<date date-type="received">
<day>22</day>
<month>09</month>
<year>2015</year></date>
<date date-type="accepted">
<day>31</day>
<month>10</month>
<year>2015</year></date></history>
<permissions>
<copyright-statement>Copyright &#x000A9; 2016, Spandidos Publications</copyright-statement>
<copyright-year>2016</copyright-year></permissions>
<abstract>
<p>Hepatocellular carcinoma (HCC) is a worldwide malignancy with poor prognosis. Liver progenitors or stem cells could be a potential therapy for HCC treatment since they migrate toward tumors. Rat liver epithelial (RLE) cells have both progenitor and stem cell-like properties. Therefore, our study elucidated the therapeutic effect of RLE cells in rat hepatoma cells. RLE cells were isolated from 10-day old rats and characterized for stem cell marker expression. RLE cells and rat hepatoma cells (H4-IIE-C3 cells) were co-cultured and divided into four groups with different ratios of RLE and hepatoma cells. Group A had only rat hepatoma cells as a control group. The ratios of rat hepatoma and RLE cells in group B, C and D were 5:1, 1:1 and 1:5, respectively. Effective inhibition of cell proliferation and migration was found in group D when compared to group A. There was a significant decrease in Bcl2 expression and increase in late apoptosis of rat hepatoma cells when adding more RLE cells. RLE cells reduced cell proliferation and migration of rat hepatoma cells. These results suggested that RLE cells could be used as a potential cell therapy.</p></abstract>
<kwd-group>
<kwd>rat liver epithelial cells</kwd>
<kwd>cell therapy</kwd>
<kwd>hepatocellular carcinoma</kwd>
<kwd>Bcl2</kwd>
<kwd>apoptosis</kwd></kwd-group></article-meta></front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Hepatocellular carcinoma (HCC) is one of the leading malignancies worldwide, particularly in Asia (<xref rid="b1-or-35-03-1622" ref-type="bibr">1</xref>&#x02013;<xref rid="b3-or-35-03-1622" ref-type="bibr">3</xref>). The treatment outcomes for those who are not candidates for resection or transplantation are usually miserable. Even after surgery, the long-term prognosis is generally unsatisfactory due to the high recurrence rate and the lack of effective systemic therapy (<xref rid="b4-or-35-03-1622" ref-type="bibr">4</xref>,<xref rid="b5-or-35-03-1622" ref-type="bibr">5</xref>). The benefit of the present target therapy remains limited (<xref rid="b6-or-35-03-1622" ref-type="bibr">6</xref>&#x02013;<xref rid="b8-or-35-03-1622" ref-type="bibr">8</xref>). Therefore, it is urgent to develop a novel therapy for these patients.</p>
<p>Progenitor and/or stem cells could be potential therapeutic agents for HCC. Bone marrow-derived mesenchymal stem cells may inhibit hepatoma cell growth and their invasiveness (<xref rid="b9-or-35-03-1622" ref-type="bibr">9</xref>&#x02013;<xref rid="b13-or-35-03-1622" ref-type="bibr">13</xref>). However, to obtain such cells from bone marrow is somewhat difficult in clinical practice. Therefore, it would be better to use liver progenitor cells to treat liver diseases.</p>
<p>Rat liver epithelial (RLE) cells from WB-F344 rats had the characteristics of progenitor or stem cells (<xref rid="b14-or-35-03-1622" ref-type="bibr">14</xref>). They could reduce tumorigenity of hepatoma CBRH-7919 cells by TGF&#x003B2;/Smad signaling. Peters <italic>et al</italic> found that co-culture of primary rat hepatocytes and RLE cells were able to enhance interleukin-6-induced acute phase protein responses (<xref rid="b15-or-35-03-1622" ref-type="bibr">15</xref>). However, to use RLE cells as a weapon to treat HCC, two main points still need to be elucidated. One is whether these RLE cells inhibit tumor growth, and the other is whether they inhibit tumor invasiveness. Therefore, our study was focussed on the understanding of cell-to-cell interaction between RLE and HCC cells.</p></sec>
<sec sec-type="methods">
<title>Materials and methods</title>
<sec>
<title>Rat hepatoma cells</title>
<p>The rat hepatoma cell line H4-IIE-C3 was obtained from the Bioresource Collection and Research Center (Hsinchu, Taiwan). Cells were cultured in the Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum (FBS), 1% penicillin/streptomycin (Gibco, Carlsbad, CA, USA) at 37&#x000B0;C in a humidified 5% CO<sub>2</sub> incubator, and were routinely sub-cultured with 0.05% trypsin in phosphate-buffer at 80&#x02013;90% confluence.</p></sec>
<sec>
<title>Isolation and culture of RLE cells</title>
<p>Pathogen-free Fisher (F344) rats were purchased from the National Laboratory Animal Center (Taipei, Taiwan). Rats were housed at Far Eastern Memorial Hospital. All animal study was performed in accordance within the guide for the care and use of laboratory animals and with the approval protocols of the Institutional Animal Care and Use Committee in the Far Eastern Memorial Hospital (FEMH; IACUC Approval No: 99-1-43-C1). Ten day old Fisher F344 rats were used to isolate RLE cells. Liver pieces were incubated in a DMEM/F12 containing 10 mM HEPES (both from Gibco), 1 mg/ml type IV collagenase (Sigma, St. Louis, MO, USA) and 1% penicillin/streptomycin at 37&#x000B0;C for 20 min. RLE cells were plated on collagen I-coated culture dishes incubated at 37&#x000B0;C in humidity incubator with 5% CO<sub>2</sub>. Cells were grown in a stem cell medium containing DMEM/F12, 2% FBS, 10 mM HEPES, 0.1% ITS Premix (Corning, Corning, NY, USA), 1&#x000D7;10<sup>&#x02212;7</sup> M dexamethasone (Sigma), 10 ng/ml human stem cell factor (SCF; eBioscience, San Diego, CA, USA), 20 ng/ml epidermal growth factor (EGF) (Sigma, St. Louis, MO, USA) and penicillin/streptomycin.</p></sec>
<sec>
<title>Western blotting</title>
<p>RLE cell lysates were collected by a lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium deoxycholate, protease inhibitors, pH 7.5). Total protein (10 mg) was separated in SDS-PAGE and transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore, Billerica, MA, USA). Blots were blocked and incubated with primary antibodies against albumin, CK19 (10712-1-AP), EpCAM (21050-1-AP) (both from Proteintech, Chicago, IL, USA) and &#x003B2;-actin as a loading control (Sigma). The appropriate HRP-conjugated secondary antibodies were used and enhanced chemiluminescence (ECL) detection system (Millipore) was employed to visualize the proteins. Images were collected by ImageQuant&#x02122; LAS 4000 (GE Healthcare Life Sciences, UK).</p></sec>
<sec>
<title>Co-culture of hepatoma and RLE cells</title>
<p>Cell culture inserts (Millipore) were used to set-up a separated co-culture system. Rat hepatoma (5&#x000D7;10<sup>4</sup>) (H4-IIE-C3) cells were placed in the 24-well plate at the bottom and RLE cells were in the culture inserts. There were 4 groups for the co-culture systems. The control group (group A) only had H4-IIE-C3 cells without any RLE cells. In group B-D, different numbers of RLE cells: 1&#x000D7;10<sup>4</sup>, 5&#x000D7;10<sup>4</sup> and 25&#x000D7;10<sup>4</sup> were placed, respectively. The ratios of RLE to H4-IIE-C3 cells were 1:5; 1:1 and 5:1, respectively.</p></sec>
<sec>
<title>Cell proliferation assay</title>
<p>Rat hepatoma H4-IIE-C3 cells were separately co-cultured with different amount of RLE cells as above (group A-D). Rat hepatoma cells from each group were harvested after 24, 48, 72 and 96 h following the co-culture, respectively. The proliferation of rat hepatoma cells was measured by the WST-1 cell proliferation assay (Roche, Mannheim, Germany). The optical density (OD) values at 450/690 nm were measured by an ELISA reader (Bio-Rad, Hercules, CA, USA).</p></sec>
<sec>
<title>Flow cytometry</title>
<p>RLE cells were stained with stem cell marker Thy-1 PE (BD Pharmingen, San Jose, CA, USA). For apoptosis assay, rat hepatoma cells were stained with FITC/Annexin V apoptosis detection kit I (BD Pharmingen) after a 3-day co-culture. All procedures were followed by the manufacturer's instructions. The data were collected on a FACSCalibur (BD Biosciences) and analyzed by FlowJo software (Tree Star, Inc., Ashland, OR, USA).</p></sec>
<sec>
<title>Migration assay</title>
<p>Transwell inserts (8-<italic>&#x000B5;</italic>m-pore) were used for the cell migration assay (Corning Inc., Tewksbury, CA, USA). In all groups, H4-IIE-C3 cells (5&#x000D7;10<sup>4</sup>) were placed on the cell inserts in a serum-free DMEM and RLE cells were cultured in stem cell medium in a 24-well plate. Group A had only H4-IIE-C3 cells without RLE cells. The cell number of RLE cells in group B-D was 1&#x000D7;10<sup>4</sup>, 5&#x000D7;10<sup>4</sup> and 25&#x000D7;10<sup>4</sup>, respectively. The migrated rat hepatoma cells were evaluated after 24-h post-incubation at 37&#x000B0;C. The migrated cells were fixed with 10% formaldehyde and washed with phosphate-buffered saline (PBS). The cells were then stained with 0.4% Giemsa (Sigma) for 2 h and washed with sterile ddH<sub>2</sub>O. Images (magnification, &#x000D7;100) were collected under a Leica microscope (Leica Microsystems, Wetzlar, Germany).</p></sec>
<sec>
<title>RNA isolation and quantitative real-time PCR</title>
<p>Total RNA was isolated from rat hepatoma cells H4-IIE-C3 by the innuPREP RNA Mini kit (Analytik Jena, Jena, Germany) according to the manufacture's protocol. The total RNA was reversely transcripted to cDNA by a High-Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The mRNA expression was analyzed by a real-time PCR Roche LightCycler 480 (Roche Applied Science, Mannheim, Germany). For real-time PCR, procedures were as follows: hot start at 95&#x000B0;C for 1 min, followed by 45 cycles of denaturing at 95&#x000B0;C for 10 sec, annealing at 58&#x000B0;C for 5 sec and extension at 72&#x000B0;C for 20 sec. PCR products were detected using 2% agarose gel to confirm the expected sizes. All primer sequences for quantitative real-time PCR analysis were: <italic>Bcl2</italic> forward, 5&#x02032;-CGA CTT TGC AGA TGT CCA-3&#x02032; and <italic>Bcl2</italic> reverse, 5&#x02032;-ATG CCG GTT CAG GTA CTC AG-3&#x02032;; <italic>Bax</italic> forward, 5&#x02032;-GAG AGG ATG GCT GGG GAG AC-3&#x02032; and <italic>Bax</italic> reverse, 5&#x02032;-TGA GTG AGG CAG TGA GGA CT-3&#x02032;; <italic>GAPDH</italic> forward, 5&#x02032;-CAC CAC CAA CTG CTT AG-3&#x02032; and <italic>GAPDH</italic> reverse, 5&#x02032;-CTT CAC CAC CTT CTT GAT G-3&#x02032;. Gene expression was analyzed after normalization to control gene GAPDH.</p></sec>
<sec>
<title>Statistical analysis</title>
<p>Comparisons among groups were performed using SPSS (SPSS, Inc., Chicago, IL, USA). All the data are reported as mean &#x000B1; SD. Comparisons between different groups for each point were performed using the one-way analysis of variance (ANOVA; and Kruskal-Wallis test), and multivariate analysis. All tests were two-tailed, and p&lt;0.05 was considered to indicate a statistically significant result.</p></sec></sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title>Characterization of RLE cells</title>
<p>Isolated RLE cells started to form a colony within 2 days and the cells were confluent after a 5-day culture (<xref rid="f1-or-35-03-1622" ref-type="fig">Fig. 1A and B</xref>). The morphology of RLE cells changed after a few passages, notably when comparing the 1st and 4th passage (<xref rid="f1-or-35-03-1622" ref-type="fig">Fig. 1C and D</xref>). Cells from the 1st passage were round, whereas the 4th passage cells became fibroblast-like, which suggested that cells became unhealthy after the 4th generation passage. Therefore, RLE cells only from the 2nd and 3rd passages were used in the present study.</p>
<p>In addition, 75% of RLE cells expressed stem cell marker Thy-1 (<xref rid="f2-or-35-03-1622" ref-type="fig">Fig. 2A</xref>). Notably, stem cell markers CK19 and EpCAM as well as hepatocyte marker albumin were detected in RLE cells (<xref rid="f2-or-35-03-1622" ref-type="fig">Fig. 2B</xref>).</p></sec>
<sec>
<title>RLE cells reduce cell proliferation of rat hepatoma cells</title>
<p>There was a decreased tendency of cell proliferation in rat hepatoma cells when the RLE cells increased (<xref rid="f3-or-35-03-1622" ref-type="fig">Fig. 3</xref>). However, there was no difference between group A and D; B and C; or C and D. A significant difference between group B and D (p=0.049) at day 4 was found, which showed that an increased cell number of RLE cells reduced the cell proliferation in rat hepatoma cells.</p></sec>
<sec>
<title>RLE cells increased apoptosis of rat hepatoma cells</title>
<p>There were no differences in early apoptosis (Annexin V<sup>+</sup>/PI<sup>&#x02212;</sup>) among the groups. Group A (hepatoma cells only) had 3% early apoptosis cells and 16% late apoptotic cells. However, the percentages of late apoptotic cells (Annexin V<sup>+</sup>/PI<sup>+</sup>) increased among the other three groups, from 10% (group B), 14% (group C) to 16% (group D) (<xref rid="f4-or-35-03-1622" ref-type="fig">Fig. 4</xref>). This shows that the apoptotic rates of rat hepatoma cells increased by adding more RLE cells.</p></sec>
<sec>
<title>RLE cells reduced cell migration of rat hepatoma cells</title>
<p>The migration of rat hepatoma was examined at the early time point (day 2) since RLE cells could reduce cell proliferation at the late time point (day 4). There was a significant decrease of the number of the migrated rat hepatoma cells in comparison between group A and D (p=0.029) (<xref rid="f5-or-35-03-1622" ref-type="fig">Fig. 5</xref>). In addition, there was a decreased trend of migrated rat hepatoma cells when RLE cell number increased. Therefore, RLE cells inhibited the migration of rat hepatoma cells.</p></sec>
<sec>
<title>Decreased Bcl2 expression in rat hepatoma cells with increasing RLE cells</title>
<p>When comparing group A (rat hepatoma cells only) to group D (rat hepatoma cells: RLE cells=1:5), there was a significant decrease of the survival gene <italic>Bcl2</italic> (p=0.005) (<xref rid="f6-or-35-03-1622" ref-type="fig">Fig. 6A</xref>). There seemed to be an increase of apoptotic gene <italic>Bax</italic> expression in group D. However, it was not statistically significant (<xref rid="f6-or-35-03-1622" ref-type="fig">Fig. 6B</xref>). It suggested that increasing RLE cells can reduce the survival of rat hepatoma cells.</p></sec></sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>Rat liver epithelial (RLE) cells isolated from adult and newborn rats have similar oval cell-like properties (<xref rid="b16-or-35-03-1622" ref-type="bibr">16</xref>). In our study, RLE cells were isolated from new-born rats and they could express progenitor cell or stem cell makers such as Thy-1, CK19, EpCAM and albumin. Thy-1 and CK19 are also expressed in human fetal livers (<xref rid="b17-or-35-03-1622" ref-type="bibr">17</xref>). Hepatic progenitor cells express the markers EpCAM, CK7, CK19, &#x003B1;-fetoprotein (AFP) and Thy-1 (<xref rid="b18-or-35-03-1622" ref-type="bibr">18</xref>&#x02013;<xref rid="b20-or-35-03-1622" ref-type="bibr">20</xref>). It suggests that RLE cells have similar properties and characteristics as hepatocyte progenitor cells.</p>
<p>Two important points were found in the present study. First, RLE cells reduced the cell proliferation and survival of hepatoma cells. Second, RLE cells could also inhibit the migration of tumor cells. Both effects significantly enhanced when RLE cell number was increased. RLE cells induced apoptosis and reduced the survival of rat hepatoma cells due to downregulation in Bcl2. Bcl2 is a survival factor and highly expressed in hepatocellular carcinoma (HCC) cells. Therefore, targeting Bcl2 could induce cell death in tumors (<xref rid="b21-or-35-03-1622" ref-type="bibr">21</xref>). It is also true that hepatocyte precursors increased apoptosis of rat hepatoma cells by decreasing Bcl2 and c-Myc (<xref rid="b14-or-35-03-1622" ref-type="bibr">14</xref>).</p>
<p>In addition, RLE cells were able to reduce the migration of rat hepatoma cells. Tumor migration is one characteristic of cancer invasiveness (<xref rid="b22-or-35-03-1622" ref-type="bibr">22</xref>,<xref rid="b23-or-35-03-1622" ref-type="bibr">23</xref>). It could come from cytokines or chemokines made by RLE cells since the co-culture system was used without cell-to-cell contact. Previous study showed cytokine IL-6 was found to increase fibrinogen and decrease albumin secretion when co-culturing epithelial cells with hepatocytes (<xref rid="b15-or-35-03-1622" ref-type="bibr">15</xref>). It is possible that IL-6 participated in the reduction of cell migration. TGF&#x003B2; and its receptors (TBRI and TBRII) are involved in tumor cell invasion through epithelial-mesenchymal transition (EMT). Therefore, increased TGF&#x003B2; receptor and Smad expression was found in rat hepatoma cells when increasing hepatocytic precursor cells (<xref rid="b14-or-35-03-1622" ref-type="bibr">14</xref>).</p>
<p>In other studies, rat liver stem cells may selectively migrate to rat HCC due to chemoattractants or factors such as VEGF, PDGF, TGF-&#x003B2;, MCP-1, IL-8, TNF-&#x003B1;, IL-1&#x003B2;, IL-6, SDF-1 or HGF (<xref rid="b24-or-35-03-1622" ref-type="bibr">24</xref>&#x02013;<xref rid="b26-or-35-03-1622" ref-type="bibr">26</xref>). Therefore, hepatocyte progenitor cells could be used for cell therapy in HCC (<xref rid="b27-or-35-03-1622" ref-type="bibr">27</xref>).</p>
<p>Stem cells for cancer therapy have been reported. Human-induced pluripotent stem cells (iPS) which can differentiate into neural stem cells (NSC) may be used as a cellular delivery vehicle for cancer gene therapy (<xref rid="b28-or-35-03-1622" ref-type="bibr">28</xref>). It remains complex that mesenchymal stem cells (MSCs) either promote or inhibit different tumors (<xref rid="tI-or-35-03-1622" ref-type="table">Table I</xref>). MSCs derived from bone marrow have characteristics in tumor suppression (<xref rid="b10-or-35-03-1622" ref-type="bibr">10</xref>&#x02013;<xref rid="b12-or-35-03-1622" ref-type="bibr">12</xref>,<xref rid="b29-or-35-03-1622" ref-type="bibr">29</xref>&#x02013;<xref rid="b36-or-35-03-1622" ref-type="bibr">36</xref>). On the contrary, some found bone marrow-derived MSCs promote tumor growth (<xref rid="b37-or-35-03-1622" ref-type="bibr">37</xref>&#x02013;<xref rid="b40-or-35-03-1622" ref-type="bibr">40</xref>). However, MSCs could act as a therapeutic tool and gene carrier for liver fibrosis and HCC (<xref rid="b41-or-35-03-1622" ref-type="bibr">41</xref>,<xref rid="b42-or-35-03-1622" ref-type="bibr">42</xref>). Whether stem cells or progenitor cells inhibit or promote tumor growth remains controversial, depending upon the stem cell origin and the difference among neoplasms.</p>
<p>In conclusion, RLE cells were able to inhibit proliferation and invasiveness of rat hepatoma cells. Therefore, RLE cells have a high potential for cell therapy in hepatoma cells.</p></sec></body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term id="G1">HCC</term>
<def>
<p>hepatocellular carcinoma</p></def></def-item>
<def-item>
<term id="G2">RLE</term>
<def>
<p>rat liver epithelial</p></def></def-item>
<def-item>
<term id="G3">AFP</term>
<def>
<p>&#x003B1;-fetoprotein</p></def></def-item>
<def-item>
<term id="G4">EMT</term>
<def>
<p>epithelial-mesenchymal transition</p></def></def-item>
<def-item>
<term id="G5">iPS</term>
<def>
<p>induced pluripotent stem</p></def></def-item>
<def-item>
<term id="G6">NSC</term>
<def>
<p>neural stem cells</p></def></def-item>
<def-item>
<term id="G7">MSC</term>
<def>
<p>mesenchymal stem cells</p></def></def-item>
<def-item>
<term id="G8">PI</term>
<def>
<p>propidium iodide</p></def></def-item></def-list></glossary>
<ack>
<title>Acknowledgments</title>
<p>We greatly appreciate the support and equipment received from Core Laboratory of Far Eastern Memorial Hospital. We also thank Miss Szu-Hua Wu and Fang-Yu Chang for their assistance. The present study was supported by grants from the Far Eastern Memorial Hospital (FEMH-2012-SCRM-A-001), the Taiwan National Science Council (NSC 100-2314-B-418-004-MY3) and the Ministry of Science and Technology, R.O.C (MOST 104-2314-B-418-018).</p></ack>
<ref-list>
<title>References</title>
<ref id="b1-or-35-03-1622"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venook</surname><given-names>AP</given-names></name><name><surname>Papandreou</surname><given-names>C</given-names></name><name><surname>Furuse</surname><given-names>J</given-names></name><name><surname>de Guevara</surname><given-names>LL</given-names></name></person-group><article-title>The incidence and Epidemiology of hepatocellular carcinoma: A global and regional perspective</article-title><source>Oncologist</source><volume>15</volume><issue>Suppl 4</issue><fpage>S5</fpage><lpage>S13</lpage><year>2010</year><pub-id pub-id-type="doi">10.1634/theoncologist.2010-S4-05</pub-id></element-citation></ref>
<ref id="b2-or-35-03-1622"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Center</surname><given-names>MM</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Forman</surname><given-names>D</given-names></name></person-group><article-title>Global cancer statistics</article-title><source>CA Cancer J Clin</source><volume>61</volume><fpage>69</fpage><lpage>90</lpage><year>2011</year><pub-id pub-id-type="doi">10.3322/caac.20107</pub-id><pub-id pub-id-type="pmid">21296855</pub-id></element-citation></ref>
<ref id="b3-or-35-03-1622"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arzumanyan</surname><given-names>A</given-names></name><name><surname>Reis</surname><given-names>HM</given-names></name><name><surname>Feitelson</surname><given-names>MA</given-names></name></person-group><article-title>Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma</article-title><source>Nat Rev Cancer</source><volume>13</volume><fpage>123</fpage><lpage>135</lpage><year>2013</year><pub-id pub-id-type="doi">10.1038/nrc3449</pub-id><pub-id pub-id-type="pmid">23344543</pub-id></element-citation></ref>
<ref id="b4-or-35-03-1622"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>AL</given-names></name><name><surname>Cha</surname><given-names>CH</given-names></name></person-group><article-title>Hepatocellular carcinoma: A comprehensive overview of surgical therapy</article-title><source>J Surg Oncol</source><volume>110</volume><fpage>712</fpage><lpage>719</lpage><year>2014</year><pub-id pub-id-type="doi">10.1002/jso.23673</pub-id><pub-id pub-id-type="pmid">24894746</pub-id></element-citation></ref>
<ref id="b5-or-35-03-1622"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raza</surname><given-names>A</given-names></name><name><surname>Sood</surname><given-names>GK</given-names></name></person-group><article-title>Hepatocellular carcinoma review: Current treatment, and evidence-based medicine</article-title><source>World J Gastroenterol</source><volume>20</volume><fpage>4115</fpage><lpage>4127</lpage><year>2014</year><pub-id pub-id-type="doi">10.3748/wjg.v20.i15.4115</pub-id><pub-id pub-id-type="pmid">24764650</pub-id><pub-id pub-id-type="pmcid">3989948</pub-id></element-citation></ref>
<ref id="b6-or-35-03-1622"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frenette</surname><given-names>C</given-names></name><name><surname>Gish</surname><given-names>R</given-names></name></person-group><article-title>Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications</article-title><source>World J Gastroenterol</source><volume>18</volume><fpage>498</fpage><lpage>506</lpage><year>2012</year><pub-id pub-id-type="doi">10.3748/wjg.v18.i6.498</pub-id><pub-id pub-id-type="pmid">22363115</pub-id><pub-id pub-id-type="pmcid">3280394</pub-id></element-citation></ref>
<ref id="b7-or-35-03-1622"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>Z</given-names></name><name><surname>Doria</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Doria</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Targeted therapies in the treatment of advanced hepatocellular carcinoma</article-title><source>Clin Med Insights Oncol</source><volume>7</volume><fpage>87</fpage><lpage>102</lpage><year>2013</year><pub-id pub-id-type="doi">10.4137/CMO.S7633</pub-id><pub-id pub-id-type="pmid">23761989</pub-id><pub-id pub-id-type="pmcid">3667684</pub-id></element-citation></ref>
<ref id="b8-or-35-03-1622"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeng</surname><given-names>KS</given-names></name><name><surname>Chang</surname><given-names>CF</given-names></name><name><surname>Jeng</surname><given-names>WJ</given-names></name><name><surname>Sheen</surname><given-names>IS</given-names></name><name><surname>Jeng</surname><given-names>CJ</given-names></name></person-group><article-title>Heterogeneity of hepatocellular carcinoma contributes to cancer progression</article-title><source>Crit Rev Oncol Hematol</source><volume>94</volume><fpage>337</fpage><lpage>347</lpage><year>2015</year><pub-id pub-id-type="doi">10.1016/j.critrevonc.2015.01.009</pub-id><pub-id pub-id-type="pmid">25680939</pub-id></element-citation></ref>
<ref id="b9-or-35-03-1622"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bayo</surname><given-names>J</given-names></name><name><surname>Marrod&#x000E1;n</surname><given-names>M</given-names></name><name><surname>Aquino</surname><given-names>JB</given-names></name><name><surname>Silva</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>MG</given-names></name><name><surname>Mazzolini</surname><given-names>G</given-names></name></person-group><article-title>The therapeutic potential of bone marrow-derived mesenchymal stromal cells on hepatocellular carcinoma</article-title><source>Liver Int</source><volume>34</volume><fpage>330</fpage><lpage>342</lpage><year>2014</year><pub-id pub-id-type="doi">10.1111/liv.12338</pub-id></element-citation></ref>
<ref id="b10-or-35-03-1622"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>IA</given-names></name><name><surname>Toh</surname><given-names>HC</given-names></name><name><surname>Ng</surname><given-names>WH</given-names></name><name><surname>Teo</surname><given-names>YL</given-names></name><name><surname>Guo</surname><given-names>CM</given-names></name><name><surname>Hui</surname><given-names>KM</given-names></name><name><surname>Lam</surname><given-names>PY</given-names></name></person-group><article-title>Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis</article-title><source>Stem Cells</source><volume>31</volume><fpage>146</fpage><lpage>155</lpage><year>2013</year><pub-id pub-id-type="doi">10.1002/stem.1247</pub-id></element-citation></ref>
<ref id="b11-or-35-03-1622"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>X</given-names></name><name><surname>Matsumoto</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Uemura</surname><given-names>T</given-names></name></person-group><article-title>Effect of human mesenchymal stem cells on the growth of HepG2 and Hela cells</article-title><source>Cell Struct Funct</source><volume>38</volume><fpage>109</fpage><lpage>121</lpage><year>2013</year><pub-id pub-id-type="doi">10.1247/csf.12029</pub-id><pub-id pub-id-type="pmid">23575155</pub-id></element-citation></ref>
<ref id="b12-or-35-03-1622"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruno</surname><given-names>S</given-names></name><name><surname>Collino</surname><given-names>F</given-names></name><name><surname>Deregibus</surname><given-names>MC</given-names></name><name><surname>Grange</surname><given-names>C</given-names></name><name><surname>Tetta</surname><given-names>C</given-names></name><name><surname>Camussi</surname><given-names>G</given-names></name></person-group><article-title>Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth</article-title><source>Stem Cells Dev</source><volume>22</volume><fpage>758</fpage><lpage>771</lpage><year>2013</year><pub-id pub-id-type="doi">10.1089/scd.2012.0304</pub-id></element-citation></ref>
<ref id="b13-or-35-03-1622"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Su</surname><given-names>XS</given-names></name><name><surname>Ye</surname><given-names>JS</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Guan</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>YF</given-names></name></person-group><article-title>Bone marrow mesenchymal stem cells suppress metastatic tumor development in mouse by modulating immune system</article-title><source>Stem Cell Res Ther</source><volume>6</volume><fpage>45</fpage><year>2015</year><pub-id pub-id-type="doi">10.1186/s13287-015-0039-8</pub-id><pub-id pub-id-type="pmid">25889932</pub-id><pub-id pub-id-type="pmcid">4425902</pub-id></element-citation></ref>
<ref id="b14-or-35-03-1622"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>WQ</given-names></name><name><surname>Li</surname><given-names>YM</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>YM</given-names></name><name><surname>Yang</surname><given-names>XQ</given-names></name><name><surname>Ge</surname><given-names>HJ</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>HM</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>HY</given-names></name></person-group><article-title>Hepatocytic precursor (stem-like) WB-F344 cells reduce tumorigenicity of hepatoma CBRH-7919 cells via TGF-&#x003B2;/Smad pathway</article-title><source>Oncol Rep</source><volume>23</volume><fpage>1601</fpage><lpage>1607</lpage><year>2010</year><pub-id pub-id-type="pmid">20428815</pub-id></element-citation></ref>
<ref id="b15-or-35-03-1622"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>SJ</given-names></name><name><surname>Vanhaecke</surname><given-names>T</given-names></name><name><surname>Papeleu</surname><given-names>P</given-names></name><name><surname>Rogiers</surname><given-names>V</given-names></name><name><surname>Haagsman</surname><given-names>HP</given-names></name><name><surname>van Norren</surname><given-names>K</given-names></name></person-group><article-title>Co-culture of primary rat hepatocytes with rat liver epithelial cells enhances interleukin-6-induced acute-phase protein response</article-title><source>Cell Tissue Res</source><volume>340</volume><fpage>451</fpage><lpage>457</lpage><year>2010</year><pub-id pub-id-type="doi">10.1007/s00441-010-0955-y</pub-id><pub-id pub-id-type="pmid">20411395</pub-id><pub-id pub-id-type="pmcid">2882052</pub-id></element-citation></ref>
<ref id="b16-or-35-03-1622"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>MS</given-names></name><name><surname>Smith</surname><given-names>JD</given-names></name><name><surname>Nelson</surname><given-names>KG</given-names></name><name><surname>Grisham</surname><given-names>JW</given-names></name></person-group><article-title>A diploid epithelial cell line from normal adult rat liver with phenotypic properties of &#x002BB;oval&#x002BC; cells</article-title><source>Exp Cell Res</source><volume>154</volume><fpage>38</fpage><lpage>52</lpage><year>1984</year><pub-id pub-id-type="doi">10.1016/0014-4827(84)90666-9</pub-id><pub-id pub-id-type="pmid">6468534</pub-id></element-citation></ref>
<ref id="b17-or-35-03-1622"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masson</surname><given-names>NM</given-names></name><name><surname>Currie</surname><given-names>IS</given-names></name><name><surname>Terrace</surname><given-names>JD</given-names></name><name><surname>Garden</surname><given-names>OJ</given-names></name><name><surname>Parks</surname><given-names>RW</given-names></name><name><surname>Ross</surname><given-names>JA</given-names></name></person-group><article-title>Hepatic progenitor cells in human fetal liver express the oval cell marker Thy-1</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><volume>291</volume><fpage>G45</fpage><lpage>G54</lpage><year>2006</year><pub-id pub-id-type="doi">10.1152/ajpgi.00465.2005</pub-id><pub-id pub-id-type="pmid">16769813</pub-id></element-citation></ref>
<ref id="b18-or-35-03-1622"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>BE</given-names></name><name><surname>Goff</surname><given-names>JP</given-names></name><name><surname>Greenberger</surname><given-names>JS</given-names></name><name><surname>Michalopoulos</surname><given-names>GK</given-names></name></person-group><article-title>Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat</article-title><source>Hepatology</source><volume>27</volume><fpage>433</fpage><lpage>445</lpage><year>1998</year><pub-id pub-id-type="doi">10.1002/hep.510270218</pub-id><pub-id pub-id-type="pmid">9462642</pub-id></element-citation></ref>
<ref id="b19-or-35-03-1622"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yovchev</surname><given-names>MI</given-names></name><name><surname>Grozdanov</surname><given-names>PN</given-names></name><name><surname>Joseph</surname><given-names>B</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Dabeva</surname><given-names>MD</given-names></name></person-group><article-title>Novel hepatic progenitor cell surface markers in the adult rat liver</article-title><source>Hepatology</source><volume>45</volume><fpage>139</fpage><lpage>149</lpage><year>2007</year><pub-id pub-id-type="doi">10.1002/hep.21448</pub-id></element-citation></ref>
<ref id="b20-or-35-03-1622"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>PP</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Yu</surname><given-names>GR</given-names></name><name><surname>Kim</surname><given-names>IH</given-names></name><name><surname>Cho</surname><given-names>YG</given-names></name><name><surname>Kim</surname><given-names>DG</given-names></name></person-group><article-title>Isolation of EpCAM<sup>+</sup>/CD133<sup>&#x02212;</sup> hepatic progenitor cells</article-title><source>Mol Cells</source><volume>36</volume><fpage>424</fpage><lpage>431</lpage><year>2013</year><pub-id pub-id-type="doi">10.1007/s10059-013-0190-y</pub-id><pub-id pub-id-type="pmid">24293012</pub-id><pub-id pub-id-type="pmcid">3887933</pub-id></element-citation></ref>
<ref id="b21-or-35-03-1622"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ni</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>X</given-names></name><name><surname>Ding</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Lewin</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>F</given-names></name></person-group><article-title>HCC cells with high levels of Bcl2 are resistant to ABT-737 via activation of the ROS-JNK-autophagy pathway</article-title><source>Free Radic Biol Med</source><volume>70</volume><fpage>194</fpage><lpage>203</lpage><year>2014</year><pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2014.02.012</pub-id><pub-id pub-id-type="pmid">24576507</pub-id></element-citation></ref>
<ref id="b22-or-35-03-1622"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Friedl</surname><given-names>P</given-names></name><name><surname>Wolf</surname><given-names>K</given-names></name></person-group><article-title>Tumour-cell invasion and migration: Diversity and escape mechanisms</article-title><source>Nat Rev Cancer</source><volume>3</volume><fpage>362</fpage><lpage>374</lpage><year>2003</year><pub-id pub-id-type="doi">10.1038/nrc1075</pub-id><pub-id pub-id-type="pmid">12724734</pub-id></element-citation></ref>
<ref id="b23-or-35-03-1622"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stivarou</surname><given-names>T</given-names></name><name><surname>Patsavoudi</surname><given-names>E</given-names></name></person-group><article-title>Extracellular molecules involved in cancer cell invasion</article-title><source>Cancers</source><volume>7</volume><fpage>238</fpage><lpage>265</lpage><year>2015</year><pub-id pub-id-type="doi">10.3390/cancers7010238</pub-id><pub-id pub-id-type="pmid">25629807</pub-id><pub-id pub-id-type="pmcid">4381257</pub-id></element-citation></ref>
<ref id="b24-or-35-03-1622"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ponte</surname><given-names>AL</given-names></name><name><surname>Marais</surname><given-names>E</given-names></name><name><surname>Gallay</surname><given-names>N</given-names></name><name><surname>Langonn&#x000E9;</surname><given-names>A</given-names></name><name><surname>Delorme</surname><given-names>B</given-names></name><name><surname>H&#x000E9;rault</surname><given-names>O</given-names></name><name><surname>Charbord</surname><given-names>P</given-names></name><name><surname>Domenech</surname><given-names>J</given-names></name></person-group><article-title>The in vitro migration capacity of human bone marrow mesenchymal stem cells: Comparison of chemokine and growth factor chemotactic activities</article-title><source>Stem Cells</source><volume>25</volume><fpage>1737</fpage><lpage>1745</lpage><year>2007</year><pub-id pub-id-type="doi">10.1634/stemcells.2007-0054</pub-id><pub-id pub-id-type="pmid">17395768</pub-id></element-citation></ref>
<ref id="b25-or-35-03-1622"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietras</surname><given-names>K</given-names></name><name><surname>Pahler</surname><given-names>J</given-names></name><name><surname>Bergers</surname><given-names>G</given-names></name><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><article-title>Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting</article-title><source>PLoS Med</source><volume>5</volume><fpage>e19</fpage><year>2008</year><pub-id pub-id-type="doi">10.1371/journal.pmed.0050019</pub-id><pub-id pub-id-type="pmid">18232728</pub-id><pub-id pub-id-type="pmcid">2214790</pub-id></element-citation></ref>
<ref id="b26-or-35-03-1622"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watnick</surname><given-names>RS</given-names></name></person-group><article-title>The role of the tumor microenvironment in regulating angiogenesis</article-title><source>Cold Spring Harb Perspect Med</source><volume>2</volume><fpage>a006676</fpage><year>2012</year><pub-id pub-id-type="doi">10.1101/cshperspect.a006676</pub-id><pub-id pub-id-type="pmid">23209177</pub-id><pub-id pub-id-type="pmcid">3543072</pub-id></element-citation></ref>
<ref id="b27-or-35-03-1622"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhong</surname><given-names>XG</given-names></name><name><surname>He</surname><given-names>S</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Deng</surname><given-names>JY</given-names></name><name><surname>Cheng</surname><given-names>B</given-names></name></person-group><article-title>Selective tropism of liver stem cells to hepatocellular carcinoma in vivo</article-title><source>World J Gastroenterol</source><volume>13</volume><fpage>3886</fpage><lpage>3891</lpage><year>2007</year><pub-id pub-id-type="doi">10.3748/wjg.v13.i28.3886</pub-id><pub-id pub-id-type="pmid">17657848</pub-id><pub-id pub-id-type="pmcid">4611226</pub-id></element-citation></ref>
<ref id="b28-or-35-03-1622"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lam</surname><given-names>DH</given-names></name><name><surname>Goh</surname><given-names>SS</given-names></name><name><surname>Lee</surname><given-names>EX</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Tay</surname><given-names>FC</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><name><surname>Balasundaram</surname><given-names>G</given-names></name><name><surname>Shahbazi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Tumor tropism of intravenously injected human-induced pluripotent stem cell-derived neural stem cells and their gene therapy application in a metastatic breast cancer model</article-title><source>Stem Cells</source><volume>30</volume><fpage>1021</fpage><lpage>1029</lpage><year>2012</year><pub-id pub-id-type="doi">10.1002/stem.1051</pub-id><pub-id pub-id-type="pmid">22311724</pub-id></element-citation></ref>
<ref id="b29-or-35-03-1622"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YR</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>XJ</given-names></name><name><surname>Wei</surname><given-names>LL</given-names></name><name><surname>Chen</surname><given-names>YN</given-names></name><name><surname>Cong</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>SF</given-names></name><name><surname>Long</surname><given-names>D</given-names></name><name><surname>Tan</surname><given-names>WD</given-names></name><name><surname>Mao</surname><given-names>YQ</given-names></name><etal/></person-group><article-title>The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo</article-title><source>Cancer Biol Ther</source><volume>7</volume><fpage>245</fpage><lpage>251</lpage><year>2008</year><pub-id pub-id-type="doi">10.4161/cbt.7.2.5296</pub-id></element-citation></ref>
<ref id="b30-or-35-03-1622"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramasamy</surname><given-names>R</given-names></name><name><surname>Lam</surname><given-names>EW</given-names></name><name><surname>Soeiro</surname><given-names>I</given-names></name><name><surname>Tisato</surname><given-names>V</given-names></name><name><surname>Bonnet</surname><given-names>D</given-names></name><name><surname>Dazzi</surname><given-names>F</given-names></name></person-group><article-title>Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth</article-title><source>Leukemia</source><volume>21</volume><fpage>304</fpage><lpage>310</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/sj.leu.2404489</pub-id></element-citation></ref>
<ref id="b31-or-35-03-1622"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khakoo</surname><given-names>AY</given-names></name><name><surname>Pati</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>SA</given-names></name><name><surname>Reid</surname><given-names>W</given-names></name><name><surname>Elshal</surname><given-names>MF</given-names></name><name><surname>Rovira</surname><given-names>II</given-names></name><name><surname>Nguyen</surname><given-names>AT</given-names></name><name><surname>Malide</surname><given-names>D</given-names></name><name><surname>Combs</surname><given-names>CA</given-names></name><name><surname>Hall</surname><given-names>G</given-names></name><etal/></person-group><article-title>Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma</article-title><source>J Exp Med</source><volume>203</volume><fpage>1235</fpage><lpage>1247</lpage><year>2006</year><pub-id pub-id-type="doi">10.1084/jem.20051921</pub-id><pub-id pub-id-type="pmid">16636132</pub-id><pub-id pub-id-type="pmcid">2121206</pub-id></element-citation></ref>
<ref id="b32-or-35-03-1622"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elzaouk</surname><given-names>L</given-names></name><name><surname>Moelling</surname><given-names>K</given-names></name><name><surname>Pavlovic</surname><given-names>J</given-names></name></person-group><article-title>Anti-tumor activity of mesenchymal stem cells producing IL-12 in a mouse melanoma model</article-title><source>Exp Dermatol</source><volume>15</volume><fpage>865</fpage><lpage>874</lpage><year>2006</year><pub-id pub-id-type="doi">10.1111/j.1600-0625.2006.00479.x</pub-id><pub-id pub-id-type="pmid">17002683</pub-id></element-citation></ref>
<ref id="b33-or-35-03-1622"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GC</given-names></name><name><surname>Ye</surname><given-names>QH</given-names></name><name><surname>Xue</surname><given-names>YH</given-names></name><name><surname>Sun</surname><given-names>HJ</given-names></name><name><surname>Zhou</surname><given-names>HJ</given-names></name><name><surname>Ren</surname><given-names>N</given-names></name><name><surname>Jia</surname><given-names>HL</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name><name><surname>Dai</surname><given-names>C</given-names></name><etal/></person-group><article-title>Human mesenchymal stem cells inhibit metastasis of a hepatocellular carcinoma model using the MHCC97-H cell line</article-title><source>Cancer Sci</source><volume>101</volume><fpage>2546</fpage><lpage>2553</lpage><year>2010</year><pub-id pub-id-type="doi">10.1111/j.1349-7006.2010.01738.x</pub-id><pub-id pub-id-type="pmid">20942864</pub-id></element-citation></ref>
<ref id="b34-or-35-03-1622"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Ju</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name></person-group><article-title>Fusion of human umbilical cord mesenchymal stem cells with esophageal carcinoma cells inhibits the tumorigenicity of esophageal carcinoma cells</article-title><source>Int J Oncol</source><volume>40</volume><fpage>370</fpage><lpage>377</lpage><year>2012</year></element-citation></ref>
<ref id="b35-or-35-03-1622"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiao</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>RC</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model</article-title><source>Cell Res</source><volume>18</volume><fpage>500</fpage><lpage>507</lpage><year>2008</year><pub-id pub-id-type="doi">10.1038/cr.2008.40</pub-id><pub-id pub-id-type="pmid">18364678</pub-id></element-citation></ref>
<ref id="b36-or-35-03-1622"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ganta</surname><given-names>C</given-names></name><name><surname>Chiyo</surname><given-names>D</given-names></name><name><surname>Ayuzawa</surname><given-names>R</given-names></name><name><surname>Rachakatla</surname><given-names>R</given-names></name><name><surname>Pyle</surname><given-names>M</given-names></name><name><surname>Andrews</surname><given-names>G</given-names></name><name><surname>Weiss</surname><given-names>M</given-names></name><name><surname>Tamura</surname><given-names>M</given-names></name><name><surname>Troyer</surname><given-names>D</given-names></name></person-group><article-title>Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation</article-title><source>Cancer Res</source><volume>69</volume><fpage>1815</fpage><lpage>1820</lpage><year>2009</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-2750</pub-id><pub-id pub-id-type="pmid">19244122</pub-id></element-citation></ref>
<ref id="b37-or-35-03-1622"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>W</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Qian</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name></person-group><article-title>Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo</article-title><source>Exp Mol Pathol</source><volume>80</volume><fpage>267</fpage><lpage>274</lpage><year>2006</year><pub-id pub-id-type="doi">10.1016/j.yexmp.2005.07.004</pub-id></element-citation></ref>
<ref id="b38-or-35-03-1622"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Djouad</surname><given-names>F</given-names></name><name><surname>Plence</surname><given-names>P</given-names></name><name><surname>Bony</surname><given-names>C</given-names></name><name><surname>Tropel</surname><given-names>P</given-names></name><name><surname>Apparailly</surname><given-names>F</given-names></name><name><surname>Sany</surname><given-names>J</given-names></name><name><surname>No&#x000EB;l</surname><given-names>D</given-names></name><name><surname>Jorgensen</surname><given-names>C</given-names></name></person-group><article-title>Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals</article-title><source>Blood</source><volume>102</volume><fpage>3837</fpage><lpage>3844</lpage><year>2003</year><pub-id pub-id-type="doi">10.1182/blood-2003-04-1193</pub-id><pub-id pub-id-type="pmid">12881305</pub-id></element-citation></ref>
<ref id="b39-or-35-03-1622"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JK</given-names></name><name><surname>Shiozawa</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Mishra</surname><given-names>A</given-names></name><name><surname>Joseph</surname><given-names>J</given-names></name><name><surname>Berry</surname><given-names>JE</given-names></name><name><surname>McGee</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><etal/></person-group><article-title>Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis</article-title><source>Nat Commun</source><volume>4</volume><fpage>1795</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/ncomms2766</pub-id><pub-id pub-id-type="pmid">23653207</pub-id><pub-id pub-id-type="pmcid">3649763</pub-id></element-citation></ref>
<ref id="b40-or-35-03-1622"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karnoub</surname><given-names>AE</given-names></name><name><surname>Dash</surname><given-names>AB</given-names></name><name><surname>Vo</surname><given-names>AP</given-names></name><name><surname>Sullivan</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>MW</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Richardson</surname><given-names>AL</given-names></name><name><surname>Polyak</surname><given-names>K</given-names></name><name><surname>Tubo</surname><given-names>R</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Mesenchymal stem cells within tumour stroma promote breast cancer metastasis</article-title><source>Nature</source><volume>449</volume><fpage>557</fpage><lpage>563</lpage><year>2007</year><pub-id pub-id-type="doi">10.1038/nature06188</pub-id><pub-id pub-id-type="pmid">17914389</pub-id></element-citation></ref>
<ref id="b41-or-35-03-1622"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aquino</surname><given-names>JB</given-names></name><name><surname>Bolontrade</surname><given-names>MF</given-names></name><name><surname>Garc&#x000ED;a</surname><given-names>MG</given-names></name><name><surname>Podhajcer</surname><given-names>OL</given-names></name><name><surname>Mazzolini</surname><given-names>G</given-names></name></person-group><article-title>Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma</article-title><source>Gene Ther</source><volume>17</volume><fpage>692</fpage><lpage>708</lpage><year>2010</year><pub-id pub-id-type="doi">10.1038/gt.2010.10</pub-id><pub-id pub-id-type="pmid">20220785</pub-id></element-citation></ref>
<ref id="b42-or-35-03-1622"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>GC</given-names></name><name><surname>Ye</surname><given-names>QH</given-names></name><name><surname>Dong</surname><given-names>QZ</given-names></name><name><surname>Ren</surname><given-names>N</given-names></name><name><surname>Jia</surname><given-names>HL</given-names></name><name><surname>Qin</surname><given-names>LX</given-names></name></person-group><article-title>Mesenchymal stem cells seldomly fuse with hepatocellular carcinoma cells and are mainly distributed in the tumor stroma in mouse models</article-title><source>Oncol Rep</source><volume>29</volume><fpage>713</fpage><lpage>719</lpage><year>2013</year></element-citation></ref></ref-list></back>
<floats-group>
<fig id="f1-or-35-03-1622" position="float">
<label>Figure 1</label>
<caption>
<p>Cell morphology of rat liver epithelial cells. (A) Two day culture. (B) Five day culture. (C) First passage. (D) Fourth passage. Magnification, objective &#x000D7;50.</p></caption>
<graphic xlink:href="OR-35-03-1622-g00.jpg"/></fig>
<fig id="f2-or-35-03-1622" position="float">
<label>Figure 2</label>
<caption>
<p>Characterization of rat liver epithelial cells. (A) Thy-1 expression in RLE cells. Cells were stained with anti-Thy-1 PE and analyzed by flow cytometry. (B) Protein expression of AFP, CK19, albumin and EpCAM in RLE cells were analyzed by western blotting and &#x003B2;-actin as a loading control. P2, 2nd passage; P3, 3rd passage.</p></caption>
<graphic xlink:href="OR-35-03-1622-g01.jpg"/></fig>
<fig id="f3-or-35-03-1622" position="float">
<label>Figure 3</label>
<caption>
<p>Reduced cell proliferation of rat hepatoma cells by RLE cells. Cell proliferation of rat hepatoma cells were detected by WST-1 assay at day 4. All the groups had the same cell number of rat hepatoma cells. Group A had only rat hepatoma cells. The ratio of hepatoma cells to RLE cells in group B-D was 5:1, 1:1 and 1:5, respectively; (<sup>&#x0002A;</sup>p&lt;0.05).</p></caption>
<graphic xlink:href="OR-35-03-1622-g02.jpg"/></fig>
<fig id="f4-or-35-03-1622" position="float">
<label>Figure 4</label>
<caption>
<p>Increased late apoptosis of rat hepatoma cells by RLE cells. Rat hepatoma cells were stained with Annexin V and propidium iodide (PI) to detect apoptotic cells by flow cytometry. The number in the right upper quadrant (Annexin V<sup>+</sup>/PI<sup>+</sup>) represented the percentages of late apoptotic cells whereas the number in right bottom quadrant (Annexin V<sup>+</sup>/PI<sup>&#x02212;</sup>) represented the percentages of early apoptotic cells.</p></caption>
<graphic xlink:href="OR-35-03-1622-g03.jpg"/></fig>
<fig id="f5-or-35-03-1622" position="float">
<label>Figure 5</label>
<caption>
<p>Reduced cell migration of rat hepatoma cells by RLE cells. Rat hepatoma cells (5&#x000D7;10<sup>4</sup>) were seeded in cell inserts and different amount of RLE cells were seeded into 24-well plates. Group A had only rat hepatoma cells. The ratios of H4-IIE-C3:RLE were 5:1, 1:1 and 1:5 in group B-D. The y-axis represented the migrated rat hepatoma cells counted under 5 different fields (at least 3 independent experiments; <sup>&#x0002A;</sup>p&lt;0.05).</p></caption>
<graphic xlink:href="OR-35-03-1622-g04.jpg"/></fig>
<fig id="f6-or-35-03-1622" position="float">
<label>Figure 6</label>
<caption>
<p>Altered apoptotic gene expression in rat hepatoma cells with increasing RLE cells. Group A had only rat hepatoma cells. The ratios of H4-IIE-C3: RLE were 5:1, 1:1 and 1:5 in group B-D. The mRNA from rat hepatoma cells were isolated and subjected to quantitative PCR for gene expression in <italic>Bcl2</italic> in (A) and <italic>Bax</italic> in (B); (<sup>&#x0002A;</sup>p&lt;0.05; <sup>&#x0002A;&#x0002A;</sup>p&lt;0.01).</p></caption>
<graphic xlink:href="OR-35-03-1622-g05.jpg"/></fig>
<table-wrap id="tI-or-35-03-1622" position="float">
<label>Table I</label>
<caption>
<p>Mesenchymal stem cells either suppress or promote tumor growth.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th valign="top" align="left">Author</th>
<th valign="top" align="center">Neoplasm</th>
<th valign="top" align="center">Effect</th>
<th valign="top" align="center">Refs.</th></tr></thead>
<tbody>
<tr>
<td valign="top" align="left">Ho <italic>et al</italic></td>
<td valign="top" align="left">Glioma</td>
<td valign="top" align="left">Suppression</td>
<td valign="top" align="center"><xref rid="b10-or-35-03-1622" ref-type="bibr">10</xref></td></tr>
<tr>
<td valign="top" align="left">Lu <italic>et al</italic></td>
<td valign="top" align="left">Murine hepatoma H22<break/>Lymphoma (YAC-1 and EL-4)<break/>Rat insulinoma INS-1 cell line</td>
<td valign="top" align="left">Inhibition</td>
<td valign="top" align="center"><xref rid="b29-or-35-03-1622" ref-type="bibr">29</xref></td></tr>
<tr>
<td valign="top" align="left">Ramasamy <italic>et al</italic></td>
<td valign="top" align="left">Tumor cell line of hematopoietic (BV173)</td>
<td valign="top" align="left">Inhibition</td>
<td valign="top" align="center"><xref rid="b30-or-35-03-1622" ref-type="bibr">30</xref></td></tr>
<tr>
<td valign="top" align="left">Khakoo <italic>et al</italic></td>
<td valign="top" align="left">Kaposi's sarcoma</td>
<td valign="top" align="left">Inhibition</td>
<td valign="top" align="center"><xref rid="b31-or-35-03-1622" ref-type="bibr">31</xref></td></tr>
<tr>
<td valign="top" align="left">Elzaouk <italic>et al</italic></td>
<td valign="top" align="left">Mouse melanoma</td>
<td valign="top" align="left">Antitumor, <italic>IL-12</italic></td>
<td valign="top" align="center"><xref rid="b32-or-35-03-1622" ref-type="bibr">32</xref></td></tr>
<tr>
<td valign="top" align="left">Li <italic>et al</italic></td>
<td valign="top" align="left">HCC</td>
<td valign="top" align="left">Enhanced tumor growth but inhibition invasiveness and metastasis</td>
<td valign="top" align="center"><xref rid="b33-or-35-03-1622" ref-type="bibr">33</xref></td></tr>
<tr>
<td valign="top" align="left">Wang <italic>et al</italic></td>
<td valign="top" align="left">Esophageal cancer</td>
<td valign="top" align="left">Declining tumorigenicity</td>
<td valign="top" align="center"><xref rid="b34-or-35-03-1622" ref-type="bibr">34</xref></td></tr>
<tr>
<td valign="top" align="left">Long <italic>et al</italic></td>
<td valign="top" align="left">HepG2 cell line</td>
<td valign="top" align="left">Growth inhibitory</td>
<td valign="top" align="center"><xref rid="b11-or-35-03-1622" ref-type="bibr">11</xref></td></tr>
<tr>
<td valign="top" align="left">Bruno <italic>et al</italic></td>
<td valign="top" align="left">HepG2 hepatoma Kaposi's sarcoma<break/>Skov-3 ovarian tumor cell lines</td>
<td valign="top" align="left">Inhibit <italic>in vitro</italic> cell growth and survival of different tumor cell lines and <italic>in vivo</italic> tumor growth</td>
<td valign="top" align="center"><xref rid="b12-or-35-03-1622" ref-type="bibr">12</xref></td></tr>
<tr>
<td valign="top" align="left">Qiao <italic>et al</italic></td>
<td valign="top" align="left">H7402 and HepG2 human liver cell line</td>
<td valign="top" align="left">Inhibit proliferation, colony-forming ability and oncogene expression both <italic>in vitro</italic> and <italic>in vivo</italic></td>
<td valign="top" align="center"><xref rid="b35-or-35-03-1622" ref-type="bibr">35</xref></td></tr>
<tr>
<td valign="top" align="left">Ganta <italic>et al</italic></td>
<td valign="top" align="left">Breast cancer</td>
<td valign="top" align="left">Antiproliferative</td>
<td valign="top" align="center"><xref rid="b36-or-35-03-1622" ref-type="bibr">36</xref></td></tr>
<tr>
<td valign="top" align="left">Zhu <italic>et al</italic></td>
<td valign="top" align="left">F6 tumor cell line<break/>SW480 tumor cell line</td>
<td valign="top" align="left">Favor growth</td>
<td valign="top" align="center"><xref rid="b37-or-35-03-1622" ref-type="bibr">37</xref></td></tr>
<tr>
<td valign="top" align="left">Djouad <italic>et al</italic></td>
<td valign="top" align="left">Melanoma tumor cells</td>
<td valign="top" align="left">Favor growth</td>
<td valign="top" align="center"><xref rid="b38-or-35-03-1622" ref-type="bibr">38</xref></td></tr>
<tr>
<td valign="top" align="left">Jung <italic>et al</italic></td>
<td valign="top" align="left">Prostate cancer</td>
<td valign="top" align="left">Promote metastasis</td>
<td valign="top" align="center"><xref rid="b39-or-35-03-1622" ref-type="bibr">39</xref></td></tr>
<tr>
<td valign="top" align="left">Karnoub <italic>et al</italic></td>
<td valign="top" align="left">Breast cancer</td>
<td valign="top" align="left">Promote metastasis</td>
<td valign="top" align="center"><xref rid="b40-or-35-03-1622" ref-type="bibr">40</xref></td></tr></tbody></table></table-wrap></floats-group></article>
